• 1
    Mignot EJ. A practical guide to the therapy of narcolepsy and hypersomnia syndromes. Neurotherapeutics 2012;9:739752.
  • 2
    Burgess CR, Scammell TE. Narcolepsy: neural mechanisms of sleepiness and cataplexy. J Neurosci 2012;32:1230512311.
  • 3
    Arnulf I, Leu S, Oudiette, D. Abnormal sleep and sleepiness in Parkinson's disease. Curr Opin Neurol 2008;21:472477.
  • 4
    Mannarino MR, Di FF, Pirro M. Obstructive sleep apnea syndrome. Eur J Intern Med 2012;23:586593.
  • 5
    Wilt TJ, MacDonald R, Ouellette J, et al. Pharmacologic therapy for primary restless legs syndrome: a systematic review and meta-analysis. JAMA Intern Med 2013;173:496505.
  • 6
    Howell MJ. Parasomnias: an updated review. Neurotherapeutics 2012;9:753775.
  • 7
    Punjabi NM, Bandeen-Roche K, Young T. Predictors of objective sleep tendency in the general population. Sleep 2003;26:678683.
  • 8
    Buysse DJ. Insomnia. JAMA 2013;309:706716.
  • 9
    Yaffe K, Laffan AM, Harrison SL, et al. Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. JAMA 2011;306:613619.
  • 10
    Fong TG, Jones RN, Marcantonio ER, et al. Adverse outcomes after hospitalization and delirium in persons with Alzheimer disease. Ann Intern Med 2012;156:848856.
  • 11
    Iranzo A, Tolosa E, Gelpi E, et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol 2013;12:443453.
  • 12
    Saper CB, Fuller PM, Pedersen NP, et al. Sleep state switching. Neuron 2010;68:10231042.
  • 13
    Huang ZL, Qu WM, Eguchi N, et al. Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine. Nat Neurosci 2005;8:858859.
  • 14
    Anaclet C, Lin JS, Vetrivelan R, et al. Identification and characterization of a sleep-active cell group in the rostral medullary brainstem. J Neurosci 2012;32:1797017976.
  • 15
    Lu J, Sherman D, Devor M, et al. A putative flip-flop switch for control of REM sleep. Nature 2006;441:589594.
  • 16
    Luppi PH, Clement O, Sapin E, et al. Brainstem mechanisms of paradoxical (REM) sleep generation. Pflugers Arch 2012;463:4352.
  • 17
    Nelson LE, Guo TZ, Lu J, et al. The sedative component of anesthesia is mediated by GABA(A) receptors in an endogenous sleep pathway. Nat Neurosci 2002;5:979984.
  • 18
    Moore JT, Chen J, Han B, et al. Direct activation of sleep-promoting VLPO neurons by volatile anesthetics contributes to anesthetic hypnosis. Curr Biol 2012;22:20082016.
  • 19
    Mohler H, Fritschy JM, Vogt K, et al. Pathophysiology and pharmacology of GABA(A) receptors. Handb Exp Pharmacol 2005; 225247.
  • 20
    Wright KP Jr, Bogan RK, Wyatt JK. Shift work and the assessment and management of shift work disorder (SWD). Sleep Med Rev 2013;17:4154.
  • 21
    Zhang L, Jones CR, Ptacek LJ, et al. The genetics of the human circadian clock. Adv Genet 2011;74:231247.
  • 22
    Hardeland R, Poeggeler B. Melatonin and synthetic melatonergic agonists: actions and metabolism in the central nervous system. Cent Nerv Syst Agents Med Chem 2012;12:189216.
  • 23
    Pandi-Perumal SR, Trakht I, Spence DW, et al. The roles of melatonin and light in the pathophysiology and treatment of circadian rhythm sleep disorders. Nat Clin Pract Neurol 2008;4:436447.
  • 24
    Boivin DB, Boudreau P, Tremblay GM. Phototherapy and orange-tinted goggles for night-shift adaptation of police officers on patrol. Chronobiol Int 2012;29:629640.
  • 25
    Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, et al. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. Eur J Neurol 2012;19:1385396.
  • 26
    Scammell TE, Winrow CJ. Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol 2011;51:243266.
  • 27
    Uslaner JM, Tye SJ, Eddins DM, et al. Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognition. Sci Transl Med 2013;5:179ra44.
  • 28
    Herring WJ, Snyder E, Budd K, et al. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology 2012;79:22652274.
  • 29
    Herring WJ, Ivgy-May N, Connor KM, et al. Effect of suvorexant, an orexin receptor antagonist, on patient-reported outcomes in patients with primary insomnia: integrated results from two phase-3 trials. Sleep 2013;36:A223.
  • 30
    Ivgy-May N, Snavely D, Minigh J, et al. Efficacy of suvorexant, an orexin receptor antagonist, in patients with primary insomnia: integrated results from 2 similarly designed phase 3 trials. Sleep 2013;36:A192.
  • 31
    Trenkwalder C, Benetos A, Grote, L, et al. Oxycodone/naloxone prolonged release—efficient short and long-term treatment for severe restless legs syndrome after failure of previous medications. Sleep 2013;36:A246.
  • 32
    Lockley SW, Dressman MA, Xiao C, et al. Tasimelteon treatment entrains the circadian clock and demonstrates a clinically meaningful benefit in totally blind individuals with non-24-hour circadian rhythms. Endocr Rev 2013;26:SUN-134 [abstract].
  • 33
    Lockley SW, Dressman MA, Xiao C, et al. RESET study demonstrates that tasimelteon maintains entrainment of melatonin and cortisol in totally blind individuals with non-24-hour circadian rhythms. Endocr Rev 2013;34:SUN-137 [abstract].
  • 34
    Kuhne S, Wijtmans M, Lim HD, et al. Several down, a few to go: histamine H3 receptor ligands making the final push towards the market? Expert Opin Investig Drugs 2011;20:16291648.
  • 35
    Schwartz JC. The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br J Pharmacol 2011;163:713721.
  • 36
    Inocente C, Arnulf I, Bastuji H, et al. Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness. Clin Neuropharmacol 2012;35:5560.
  • 37
    Winkelmann J, Schormair B, Lichtner P, et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet 2007;39:10001006.
  • 38
    Stefansson H, Rye DB, Hicks A, et al. A genetic risk factor for periodic limb movements in sleep. N Engl J Med 2007;357:639647.
  • 39
    Schormair B, Kemlink D, Roeske D, et al. PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nat Genet 2008;40:946948.
  • 40
    Winkelmann J, Czamara D, Schormair B, et al. Genome-wide association study identifies novel restless legs syndrome susceptibility loci on 2p14 and 16q12.1. PLoS Genet 2011;7:e1002171.
  • 41
    Oexle K, Schormair B, Ried JS, et al. Dilution of candidates: the case of iron-related genes in restless legs syndrome. Eur J Hum Genet 2013;21:410414.
  • 42
    Mahler SV, Smith RJ, Moorman DE, et al. Multiple roles for orexin/hypocretin in addiction. Prog Brain Res 2012;198:79121.
  • 43
    Oishi Y, Williams RH, Agostinelli L, et al. Role of the medial prefrontal cortex in cataplexy. J Neurosci 2013;33:97439751.
  • 44
    Bartus RT, Baumann TL, Siffert J, et al. Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology 2013;80:16981701.